TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Spatial Analysis and Validation of Glioblastoma on 7 T MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Supratentorial tumour~* Suspected GBM on diagnostic MRI~* Eligible for biopsy~* Minimum age 18 years or older~* World Health Organization (WHO) Performance scale ≤2~* American Society of Anaesthesiologist (ASA) class ≤ 3~* Understanding of the Dutch language~* Ability to comply to study procedure~Exclusion Criteria:~* Recurrent tumour~* Tumour location deemed unfit for extra biopsies~* Prior radiotherapy to the skull~* Prior chemotherapy~* World Health Organization (WHO) Performance scale ≥ 3~* American Society of Anaesthesiologist (ASA) class ≥ 3~* Eligibility for immediate debulking~* Contra-indications for gadolinium~* Contra-indications for the MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biopsy (Type: EXPERIMENTAL): Subjects will receive a 7 T MRI and one additional biopsy to their standard diagnostic biopsies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals recruited into this study will be patients presenting to the Urogynecology and Minimally Invasive Surgical Group for consultation for hysterectomy.~Exclusion Criteria:Individuals who are not candidates for laparoscopic surgery~* Medical Condition that does not allow pneumoperitoneum~* Medical Condition that does not allow proper ventilation during anesthesia~* Uterine size precluding access to the uterine artery~* Pelvic Organ Prolapse amendable to a vaginal approach

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- LH Group (Type: ACTIVE_COMPARATOR): The LH Group includes individuals undergoing conventional laparoscopic hysterectomy, total or supracervical.
- RH Group (Type: ACTIVE_COMPARATOR): The RH Group includes individuals undergoing Robot-Assisted laparoscopic hysterectomy, total or supracervical.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Corneal Neurotization as a Treatment for Neurotrophic Keratopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with neurotrophic cornea~Exclusion Criteria:~* Patients with history of penetrating keratoplasty

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Corneal neurotization (Type: EXPERIMENTAL): Patients will undergo the corneal neurotization as described in the protocol. Their pre and post-procedure corneal sensation will be measured as a primary outcome measure. Secondary outcome measures will include visual acuity, corneal opacity, NEI VFQ, and confocal microscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Different Levels of Patient Education for Care of Ostomy Site

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal to or greater than 18 years of age at the time of consent.~* Scheduled to undergo surgery at IU Health North Hospital that will results in a temporary or permanent colostomy or ileostomy for a benign or malignant disease process.~* Are willing and able to provide written informed consent for participation in the study and authorization for release of health information.~* Are willing and able to attend up to two additional clinic visits at IU Health North Hospital for the purpose of ostomy teaching and care.~* Subjects who currently do NOT have a urostomy or any other type of urinary diversion and/or are NOT planning to have a urostomy or any other type of urinary diversion as part of the surgery procedures at the time of their surgery for placement of colostomy or ileostomy.~* Subjects who do NOT have any history of prior colostomy or ileostomy.~Exclusion Criteria:~* Subjects not meeting any of the above eligibility criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Standard (Type: ACTIVE_COMPARATOR): Subjects will receive standard ostomy education.
- Pre-Operative Education (Type: EXPERIMENTAL): In addition to standard ostomy education, subjects will receive additional education pre-operatively.
- Two-week Post Operative Education (Type: EXPERIMENTAL): In addition to standard ostomy education, subjects will receive additional education two weeks following surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Men, at least 18 years of age, willing to participate in the study and willing to regularly attempt sexual activity.~2. Patients with histologically proven prostate cancer.~3. Provide signed informed consent.~4. Patients with normal erectile function defined as a combined score \>=8 of questions 3 and 4 of the IIEF.~5. Agree not to use any other ED treatment during the study.~Exclusion Criteria:~1. Use of any treatment for ED before the start of the study.~2. History of pelvic surgery (including radical prostatectomy)~3. History of penile implant~4. The presence of penile deformity that makes sexual intercourse difficult or impossible.~5. Patients with chronic stable angina treated with long-acting nitrates, or patients with chronic stable angina who have required short-acting nitrates in the last 90 days, or angina occurring during sexual intercourse in the last 6 months.~6. Patients with unstable angina, history of myocardial infarction or coronary artery bypass graft surgery or percutaneous coronary intervention (eg, angioplasty or stent placement) within 90 days before screening.~7. Any supraventricular arrhythmia with an uncontrolled ventricular response (mean heart rate \>100 bpm) at rest despite medical or device therapy, or any history of spontaneous or induced sustained ventricular tachycardia (heart rate \>100 bpm for 30 sec) despite medical or device therapy, or the presence of an automatic internal cardioverter-defibrillator.~8. A history of sudden cardiac arrest despite medical or device therapy.~9. Any evidence of congestive heart failure or a new, significant conduction defect within 90 days before screening.~10. Systolic blood pressure \>170 or \<90 mm Hg or diastolic blood pressure \>100 or \<50 mm Hg, or patients with a history of malignant hypertension.~11. History of significant central nervous system injuries (including stroke and spinal cord injury) within the 6 months before screening.~12. History of HIV infection.~13. Any condition that would interfere with the patient's ability to provide informed consent or comply with study instructions, would place patient at increased risk, or might confound the interpretation of the study results.~14. Treatment with cancer chemotherapy.~15. History of drug, alcohol, or substance abuse within the 6 months before screening.~16. Have any condition, limitation, or disease that could, in the judgment of the investigator, preclude evaluation of response to tadalafil.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electrosurgical Unipolar Vessel Sealing in Vaginal Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* uterine size \<12 weeks.~* presence of benign cause for the hysterectomy e.g. fibroid uterus, perimenopausal beeding not responding to medical treatment or complex endometrial hyperplasia without atypia.~* Absence of significant scarring in the pelvis from previous surgeries.~Exclusion Criteria:~* Suspected or known gynecological malignancy.~* uterine size \>12 weeks.~* Endometriosis~* Presence of adnexal mass.~* cervix flushed with the vagina.~* presence of significant scarring in the pelvic area from previous surgery.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Unipolar electrocautery (Type: EXPERIMENTAL): vaginal hysterectomy using Unipolar electrocautery
- Purohit's technique (Type: ACTIVE_COMPARATOR): Vaginal hysterectomy using Purohit's technique

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Cryopreserved buffy coat pooled platelets will be infused, after being thawed, in inpatients at U.O. of Hematology -Policlinic P. Giaccone-Palermo, falling into one of the following categories:~* Stable clinical conditions and no complications with platelets ≤ 10,000/microliter;~* With active bleeding and ≤ 20,000 platelets/microliter;~* In the presence of: high blood pressure, high fever, rapid drop in platelets, infection, chemotherapy, coagulation abnormalities with ≤ 20,000 platelets/microliter.~Exclusion Criteria:~Patients~* Suffering from congenital immunodeficiency~* Allogeneic bone marrow transplant candidates~* Bone Marrow Donors for transplantation~* Undergoing bone marrow transplant or~* Suffering from Hodgkin's disease and treated with purine analogues (Fludarabine, cladribine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patients with severe thrombocytopenia (Type: OTHER): Intervention Patients with severe thrombocytopenia with an active bleeding, in preparation for surgery, or after chemotherapy (prophylaxis of bleeding),will receive transfusion of Pooled Platelets Cryopreserved In DMSO With a New System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of WA-NG (NG-IMT) Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
\*\*The following Inc. \& Exc. are sample and not completed list \*\*~Main Exclusion Criteria:~* Patients with bilateral, stable, moderate to profound central vision impairment due to bilateral central scotoma associated with end-stage macular degeneration, defined as retinal findings of bilateral, geographic atrophy or disciform scar with foveal involvement.~* Patients must have distance BCVA between 20/80 and 20/800, and adequate peripheral vision in one eye (the non-implanted eye) to allow navigation~* Patients must achieve at least a five letter improvement on the ETDRS chart in the eye scheduled for surgery, with the external telescope simulator (ETS)~* Patients must be available for the study duration of 12 months~* Patients must be alert, mentally competent, and able to understand and comply with the requirements of the clinical trial, and be personally motivated to abide by the requirements and restrictions of the clinical trial.~Main Exclusion Criteria:~* Evidence of active CNV on fluorescein angiography or treatment for CNV within the past six months.~* Patients who may require fellow eye cataract extraction and intraocular lens implantation during the 12 months following WA-NG telescope implantation. If fellow eye cataract extraction is anticipated, this procedure should be performed at least 30 days prior to enrollment in the clinical study.~* Patients who have had or are expected to have ophthalmic related surgery within the 30 days preceding implantation of the device.~* Patients who have undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of surgery for either refractive or therapeutic purposes.~* Patients participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WA-NG (NG-IMT) Telescope Prothesis (Type: EXPERIMENTAL): Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Expiratory Pressure Modulation in Moderate to Severe COPD Patients - Phase 1b

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years who are contractually capable and mentally able to understand and follow the instructions of the study personnel~2. Signed informed consent~3. Moderate to severe COPD patients (FEV1/FVC ratio \<70% and FEV1 \< 50% pred) with chronic hypercapnic respiratory failure (PaCO2 \>45 mmHg)~4. Currently using NIV~Exclusion Criteria:~1. Acute exacerbation of COPD, acute respiratory failure (ph \< 7,35 and/or respiratory rate \>30/min)~2. Unstable heart failure~3. Cardiac failure with dehydration~4. Pregnancy/breastfeeding women~5. Pneumothorax/-mediastinum~6. Increased risk of pneumothorax, pneumomediastinum or venous air embolism~7. In the opinion of the investigator, the patient is unsuitable for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Single centre, single arm (Type: EXPERIMENTAL): Noninvasive ventilation with expiratory modulation. Assessment of comfort and blood gases.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Direct Current Stimulation for Freezing of Gait

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. age 18- 80~2. Parkinson's disease stages 2-3 Hoehn and Yahr.~3. Presence of Freezing of Gait~4. Stable medication regimen~5. Time to complete TUG \>12 seconds~Exclusion Criteria:~1. medical condition that would interfere with walking and training for 30 minutes~2. unable to perform timed up and go in the off condition~3. history of seizures~4. implanted deep brain stimulator, pacemaker or any other electronic device.~5. dementia~6. Adults unable to consent, individuals who are not yet adults (infants, children, teenagers) pregnant women, prisoners will not be considered for participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- tDCS+ LT (Type: EXPERIMENTAL): Transcranial direct current stimulation(tDCS) plus locomotor training (LT) 3x per week for 3 consecutive weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult caucasian patient~* Polypoidal choriodal vasculopathy~* Informed written consent~Exclusion Criteria:~* History of cephalic radiotherapy~* Absence of affiliation to social security or universal health coverage (CMU)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Early Oral Supplementation in Improving Nutritional Status in Patients Undergoing Hematopoietic Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing an autologous or reduced intensity conditioning (RIC) allogeneic HSCT~* A serum albumin greater than or equal to 2.5 g/dL~* Able to understand and sign consent~Exclusion Criteria:~* Patients who have malabsorption problems, such as ulcerative colitis, irritable bowel syndrome, Crohn's disease, bowel surgery such as gastric bypass, and celiac disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Supportive care (Boost Plus, Pro-Stat 101) (Type: EXPERIMENTAL): Participants receive Boost Plus PO BID or Pro-Stat 101 PO BID beginning one week before scheduled HSCT and continuing until hospital discharge. If participants do not tolerate the Boost Plus or Pro-Stat, they receive a milkshake PO QD as an alternative.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Collateral-based reSetting of Endovascular Treatment Time Window for Stroke (CoSETS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Acute ischemic stroke~* Age ≥ 19 years old~* Modified Rankin Scale score before qualifying stroke, 0 or 1~* Baseline National Institute of Health Stroke Scale, 5 or greater~* Baseline Alberta Stroke Program Early Computed Tomographic Sign, 6 or greater~* Documented occlusion of relevant intracranial internal carotid artery or middle cerebral artery M1 segment on multiphase CT angiogram~* Starting of endovascular treatment (femoral artery puncture) should be possible between 150 minutes and 600 minutes after last seen well time.~* Nonenhanced CT and multiphase CT angiogram should be obtained in the participating hospital~* If indicated, intravenous administration of tissue plasminogen activator should be given.~Exclusion Criteria:~* Femoral puncture is impossible~* Pregnancy or positive on serum beta-hCG test~* Known uncontrollable allergic reaction to iodized contrast media~* Intracranial cerebral artery dissection~* Suspected chronic occlusion of the relevant intracranial large artery~* In hospital stroke~* Bilateral internal carotid artery or middle cerebral artery occlusion~* Underlying severe medical or surgical disease which may affect treatment response.~* Clinical follow is impossible because of social or medical problems.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: patients with good collateral (Type: NO_INTERVENTION): None
- Group 2a, patient with poor collaterals (Type: EXPERIMENTAL): Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
- Group 2b, patients with poor collaterals (Type: NO_INTERVENTION): Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy